HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Disc Medicine (NASDAQ:IRON), maintaining a $70 price target on the stock.

April 01, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Disc Medicine receives a reiterated Buy rating and a maintained $70 price target from HC Wainwright & Co.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. A reiterated Buy rating and a maintained price target suggest a strong vote of confidence in Disc Medicine's potential, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90